287 related articles for article (PubMed ID: 12195411)
1. [Increased in vitro and ex vivo proliferation of erythroid precursors induced by calcitriol in chronic renal failure. Synergistic effect with rHuEPO].
Aucella F; Gatta G; Vigilante M; Scalzulli RP; Mantuano S; Carotenuto M; Stallone C
G Ital Nefrol; 2002; 19(2):137-42. PubMed ID: 12195411
[TBL] [Abstract][Full Text] [Related]
2. Calcitriol increases burst-forming unit-erythroid proliferation in chronic renal failure. A synergistic effect with r-HuEpo.
Aucella F; Scalzulli RP; Gatta G; Vigilante M; Carella AM; Stallone C
Nephron Clin Pract; 2003; 95(4):c121-7. PubMed ID: 14694273
[TBL] [Abstract][Full Text] [Related]
3. [Calcitriol increases burst forming unit-erythroid (BFU-E) in vitro proliferation in chronic uremia. Synergic effect with DNA recombinant erythropoietin (rHu-Epo)].
Aucella F; Gatta G; Vigilante M; Scalzulli RP; Mantuano S; Carotenuto M; Stallone C
Minerva Urol Nefrol; 2001 Mar; 53(1):1-5. PubMed ID: 11346713
[TBL] [Abstract][Full Text] [Related]
4. Desferrioxamine improves burst-forming unit-erythroid (BFU-E) proliferation in haemodialysis patients.
Aucella F; Vigilante M; Scalzulli P; Musto P; Crisetti A; Modoni S; Carotenuto M; Stallone C
Nephrol Dial Transplant; 1998 May; 13(5):1194-9. PubMed ID: 9623553
[TBL] [Abstract][Full Text] [Related]
5. Recombinant human erythropoietin resistance in hemodialysis. Effects of paired filtration dialysis.
Carozzi S; Nasini MG; Santoni O; Tirotta A; Sanna A
ASAIO J; 1997; 43(5):M535-8. PubMed ID: 9360100
[TBL] [Abstract][Full Text] [Related]
6. Synergistic effect of desferrioxamine and recombinant erythropoietin on erythroid precursor proliferation in chronic renal failure.
Aucella F; Vigilante M; Scalzulli P; Musto P; Prencipe M; Valente GL; Carotenuto M; Stallone C
Nephrol Dial Transplant; 1999 May; 14(5):1171-5. PubMed ID: 10344357
[TBL] [Abstract][Full Text] [Related]
7. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
8. Potential role of parathyroid hormone as an inhibitor of erythropoiesis in the anemia of renal failure.
McGonigle RJ; Wallin JD; Husserl F; Deftos LJ; Rice JC; O'Neill WJ; Fisher JW
J Lab Clin Med; 1984 Dec; 104(6):1016-26. PubMed ID: 6501997
[TBL] [Abstract][Full Text] [Related]
9. [The effect of calcitriol on renal anemia in patients under chronic hemodialysis].
Abou-Khalil N; Makó J
Orv Hetil; 1996 Jul; 137(27):1469-72. PubMed ID: 9173368
[TBL] [Abstract][Full Text] [Related]
10. Perturbation of autocrine/paracrine loops of burst-forming units of erythroid-derived cells in rHuEPO-hyporesponsive hemodialysis patients.
Nakao K; Wada J; Ota K; Ichikawa H; Akagi S; Okamoto A; Hida K; Nagake Y; Makino H
Am J Kidney Dis; 2003 Mar; 41(3):624-36. PubMed ID: 12612986
[TBL] [Abstract][Full Text] [Related]
11. In vivo effects of recombinant human erythropoietin on bone marrow hematopoiesis in patients with chronic renal failure.
Biljanović-Paunović L; Djukanović L; Lezaić V; Stojanović N; Marisavljević D; Pavlović-Kentera V
Eur J Med Res; 1998 Dec; 3(12):564-70. PubMed ID: 9889177
[TBL] [Abstract][Full Text] [Related]
12. Ca++ and 1,25(OH)2D3 regulate in vitro and in vivo the response to human recombinant erythropoietin in CAPD patients.
Carozzi S; Ramello A; Nasini MG; Schelotto C; Caviglia PM; Cantaluppi A; Salit M; Lamperi S
Adv Perit Dial; 1990; 6():312-5. PubMed ID: 1982836
[TBL] [Abstract][Full Text] [Related]
13. [Possible role of soluble erythropoietin receptors in renal anemia].
Sakaguchi M; Maeda Y; Naiki Y; Hasegawa H; Kanamaru A
Nihon Jinzo Gakkai Shi; 2002 Oct; 44(7):524-9. PubMed ID: 12476588
[TBL] [Abstract][Full Text] [Related]
14. Orally administrated Juzen-taiho-to/TJ-48 ameliorates erythropoietin (rHuEPO)-resistant anemia in patients on hemodialysis.
Nakamoto H; Mimura T; Honda N
Hemodial Int; 2008 Oct; 12 Suppl 2():S9-S14. PubMed ID: 18837771
[TBL] [Abstract][Full Text] [Related]
15. Erythropoiesis after kidney transplantation: the role of erythropoietin, burst promoting activity and early erythroid progenitor cells.
Lezaic V; Biljanovic-Paunovic L; Pavlovic-Kentera V; Djukanovic L
Eur J Med Res; 2001 Jan; 6(1):27-32. PubMed ID: 11313188
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin converting enzyme inhibitors impair recombinant human erythropoietin induced erythropoiesis in patients with chronic renal failure.
Qureshi IZ; Abid K; Ambreen F; Qureshi AL
Saudi Med J; 2007 Feb; 28(2):193-6. PubMed ID: 17268695
[TBL] [Abstract][Full Text] [Related]
17. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
Ross EA; Tian J; Abboud H; Hippensteel R; Melnick JZ; Pradhan RS; Williams LA; Hamm LL; Sprague SM
Am J Nephrol; 2008; 28(1):97-106. PubMed ID: 17914251
[TBL] [Abstract][Full Text] [Related]
18. Red blood cell membrane lipid peroxidation and resistance to erythropoietin therapy in hemodialysis patients.
Gallucci MT; Lubrano R; Meloni C; Morosetti M; Manca di Villahermosa S; Scoppi P; Palombo G; Castello MA; Casciani CU
Clin Nephrol; 1999 Oct; 52(4):239-45. PubMed ID: 10543326
[TBL] [Abstract][Full Text] [Related]
19. The evaluation of postdialysis L-carnitine administration and its effect on weekly requiring doses of rHuEPO in hemodialysis patients.
Kadiroglu AK; Yilmaz ME; Sit D; Kara IH; Isikoglu B
Ren Fail; 2005; 27(4):367-72. PubMed ID: 16060121
[TBL] [Abstract][Full Text] [Related]
20. [Reticulocyte response after immediate withdrawal of recombinant human erythropoietin in chronic hemodialysis patients].
Caramelo C; Soto C; Neira F; López MD; Jiménez S; Albalate M; de Oña R; Llamas P; Deudero JJ
Nefrologia; 2004; 24(4):351-6. PubMed ID: 15455495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
